Quick Answer
Vaxcyte, Inc. reported Diluted EPS of $5.63 per share (loss) for fiscal year 2025.
Vaxcyte, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.63 | -48.2% |
| 2024 | -$3.80 | +8.2% |
| 2023 | -$4.14 | -20.3% |
| 2022 | -$3.44 | -78.2% |
| 2021 | -$1.93 | +36.1% |
| 2020 | -$3.02 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.56 | -88.0% | -27.9% |
| June 30, 2025 | -$1.22 | -10.9% | -17.3% |
| March 31, 2025 | -$1.04 | -22.4% | -25.3% |
| September 30, 2024 | -$0.83 | +8.8% | +24.5% |
| June 30, 2024 | -$1.10 | -57.1% | -29.4% |
| March 31, 2024 | -$0.85 | -21.4% | +6.6% |
| September 30, 2023 | -$0.91 | +2.2% | -30.0% |
| June 30, 2023 | -$0.70 | +12.5% | +0.0% |
- Vaxcyte, Inc. showed a decrease of -48.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Vaxcyte, Inc.’s diluted eps has declined by 86.4% (from $3.02 per share (loss) to $5.63 per share (loss)).
- The most recent figure is from Vaxcyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: